The ALK ligand, ALKAL2, has higher expression in non-MYCN- versus MYCN-amplified tumours [94], although it is still capable of enhancing MYCN-driven neuroblastoma even in the absence of hotspot ALK mutations [95]. Here, MYCN is linked to neoplasm.